Cyclerion reports Q2 net loss $13.4M; positive CY6463 data in MELAS and CIAS studies

Cyclerion Therapeutics, Inc.

2022-Q2 EPS reported -$0.61 revenue$1,017,000

Cash $30.3M at June 30, 2022; net loss $13.4M vs $16.2M year ago.
CY6463 showed improvements in biomarkers, cognitive performance, safety in MELAS and CIAS studies.
Appointed Steven E. Hyman, M.D. to Board of Directors effective July 25, 2022.
Enrollment ongoing in Phase 2a Alzheimer's disease with vascular pathology study; topline results expected 2023.
R&D expenses $10.2M, G&A $3.5M; both down YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.